Get started
Author

Michaël R. Paillasse

Observed names: M. Paillasse, M.R. Paillasse, Michael Paillasse, Michael R Paillasse, Michael R. Paillasse, PAILLASSE, Michaël, Paillasse, M.R., Paillasse, Michaël, michael Paillasse
Observed institutions: Université Toulouse III - Paul Sabatier, Inserm, Centre de Recherches en Cancérologie de Toulouse, Centre de Physiopathologie de Toulouse-Purpan, Institut Claudius Regaud, Hôpital Purpan, Université de Toulouse
ORCID: 0000-0001-6418-8303
Observed ORCID: 0000-0001-6418-8303
OpenAlex ID: A5019230486
Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins
2010 · Caroline Subra, David Grand, et al. · Journal of Lipid Research · 635
PDF
Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties
2013 · Philippe de Medina, Michael R. Paillasse, et al. · Nature Communications · 132
PDF
Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands
2010 · Philippe de Medina, Michael R. Paillasse, et al. · Proceedings of the National Academy of Sciences · 127
PDF
5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells
2013 · Gregory Segala, Philippe de Medina, et al. · Biochemical Pharmacology · 73
Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases
2009 · Philippe de Medina, Michael R. Paillasse, et al. · Journal of Medicinal Chemistry · 71
Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion
2009 · Michael R. Paillasse, Philippe de Medina, et al. · Journal of Lipid Research · 71
PDF
Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors
2010 · Philippe de Medina, Salvatore Genovese, et al. · Molecular Pharmacology · 66
Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands
2011 · Philippe de Medina, Michael R. Paillasse, et al. · Chemistry and Physics of Lipids · 60
The NR4A nuclear receptors as potential targets for anti-aging interventions
2014 · Michael R. Paillasse, Philippe de Medina · Medical Hypotheses · 47
Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles
2012 · Michael R. Paillasse, Nathalie Saffon, et al. · Journal of Lipid Research · 42
Targeting Cholesterol Homeostasis to Fight Hearing Loss: A New Perspective
2015 · Brigitte Malgrange, Isabel Varela-Nieto, et al. · Frontiers in Aging Neuroscience · 34
PDF
Disrupting Mitochondrial Electron Transfer Chain Complex I Decreases Immune Checkpoints in Murine and Human Acute Myeloid Leukemic Cells
2021 · Raquel Luna-Yolba, Justine Marmoiton, et al. · Cancers · 17
PDF
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy
2022 · Michael R. Paillasse, Michael Esquerré, et al. · Cancer Research Communications · 15
PDF
Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig
2015 · Anette Fransson, Philippe de Medina, et al. · Frontiers in Aging Neuroscience · 15
PDF
EVT‐701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti‐tumor activity in models of solid cancers
2021 · Raquel Luna Yolba, Virgile Visentin, et al. · Pharmacology Research & Perspectives · 12
PDF
Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation
2006 · Michaël R. Paillasse, Céline Deraeve, et al. · Molecular Pharmacology · 9
Abstract 3768: Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small-molecule inhibitors for cancer immunotherapy
2018 · Pierre Fons, Andy Bell, et al. · Cancer Research · 5
Abstract 3970: Targeting the adenosine immunosuppressive pathway for cancer immunotherapy with small molecule agents
2017 · Pierre Fons, Michael Esquerré, et al. · Cancer Research · 5
Abstract 5244: SIRPα knockout iPSC-derived macrophages (iMACs) are resistant to CD47-dependent inhibition of phagocytosis and efficiently kill tumor cells in pre-clinical models
2024 · Kathrin Haake, Michela Mirenda, et al. · Cancer Research · 4
Abstract 1731: EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy
2021 · Andrew Payne, Pierre Fons, et al. · Cancer Research · 4
Abstract 3203: EVOcells Oncology: Tailored genetic engineering of iPSC-derived immune effector cells and combination with the right biologic therapeutics result in optimal killing of primary tumor cells from patients
2023 · Michael Esquerré, Audrey Holtzinger, et al. · Cancer Research · 2
Abstract 956: The liver-X-receptor-α is involved in the induction by Tamoxifen of breast cancer cell differentiation and death
2012 · Gregory Segala, Philippe de Medina, et al. · Cancer Research · 2
Abstract 938: Discovery of Dendrogenin A as the first endogenous alkylaminooxysterol present in mammals with potent cell differentiation and anticancer activity
2011 · Marc Poirot, Philippe de Medina, et al. · Cancer Research · 2
1515 Gene edited iPSC-derived macrophages (iMACs) show increased phagocytosis in pre-clinical tumor models
2023 · Kathrin Haake, Michela Mirenda, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
337 Development of potent iPSC-derived macrophages (iMACs) for off-the-shelf cancer immunotherapy – a new cell type in the EVOcells platform
2022 · Kathrin Haake, Michela Mirenda, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Works count: 101
Citation count: 1,458
H-index: 14
I10-index: 15
Year
Topic
Type